PetVivo Holdings, Inc. (OTCQX: PETV) will hold a conference call on Friday, August 14, 2026, at 5:00 p.m. Eastern time to discuss financial results for the fiscal first quarter ended June 30, 2026. The Minneapolis-based biomedical company, which focuses on medical devices and therapeutics for equines and companion animals, stated that the financial results will be issued in a press release prior to the call. This disclosure ensures investors have access to the key performance metrics before the management team provides context and answers questions during the live event.

The conference call is scheduled for Friday, August 14, 2026, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time). PetVivo management will host the presentation, followed by a question-and-answer period. The company has provided specific dial-in details for participants who wish to join the audio portion of the call.

Investors unable to attend via phone can access the webcast live or view the replay through the link provided by the company. A replay of the webcast will also be available via a link in the Investors section of the company’s website at petvivo.com/investors following the conclusion of the call. This multi-channel approach aims to maximize accessibility for shareholders and analysts monitoring the emerging biomedical firm.

PetVivo Holdings, Inc., operating through wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp, and PetVivo AI, Inc., is currently focused on the manufacturing, commercialization, and licensing of innovative medical devices. The company’s strategy leverages human therapies for companion animals, aiming for accelerated timelines to revenue compared to more stringently regulated pharmaceuticals. Its lead product, SPRYNG with OsteoCushion technology, an intra-articular injection for joint-related afflictions in cats, dogs, and horses, remains available for commercial sale.

The company noted that its portfolio includes twelve patents and six trade secrets protecting its biomaterials, products, production processes, and methods of use. Forward-looking statements regarding development and commercial timelines are subject to risks detailed in the Annual Report on Form 10-K for the year ended March 31, 2026. The company disclaims any obligation to update these statements based on new information or future events.

PetVivo Holdings, Inc., along with its wholly-owned subsidiaries PetVivo Animal Health, Inc., Cosmeta Corp, and PetVivo AI, Inc., announced on July 28, 2026, that it has entered into a Termination and Settlement Agreement with VetStem, Inc. Effective July 24, 2026, the agreement resolves all outstanding matters between the entities and terminates the Exclusive License and Supply Agreement for the PrecisePRP product line. By settling these claims for a fixed cost of $75,000, PetVivo eliminates lingering financial liabilities, including accrued royalties and milestone payments, allowing management to concentrate fully on advancing its proprietary technology portfolio, specifically the SPRYNG product with OsteoCushion Technology.

The settlement establishes an orderly transition of remaining inventory and commercial activities. Under the terms, all financial obligations arising from the prior license agreement—including outstanding invoices, accrued royalty obligations, and milestone payment obligations—have been fully satisfied and extinguished. The agreement includes mutual releases regarding substantially all claims, subject only to customary continuing obligations. PetVivo’s sole remaining financial obligation is an aggregate payment of $75,000, structured as two scheduled cash payments.

Settlement Terms and Inventory Reconciliation

The agreement includes an inventory reconciliation mechanism; if the transferred inventory is determined to be less than agreed minimum quantities following verification, PetVivo may be required to make an additional payment. The remaining PrecisePRP product inventory will be returned to VetStem. Notably, the previously issued warrant held by VetStem to purchase 250,000 shares of PetVivo common stock remains in full force and effect according to its existing terms.

John Lai, Chief Executive Officer of PetVivo Holdings, stated that the agreement represents the successful conclusion of the commercial relationship with VetStem, enabling both companies to move forward independently. He emphasized that the resolution allows PetVivo to devote its full attention and resources to advancing proprietary technologies, including SPRYNG with OsteoCushion Technology, while executing broader strategic growth initiatives.

Strategic Focus Shift

With the PrecisePRP license terminated, PetVivo is pivoting entirely toward its internal pipeline. The company’s lead product, SPRYNG with OsteoCushion Technology, is a veterinarian-administered intra-articular injection for managing lameness and joint afflictions in cats, dogs, and horses. This product is currently available for commercial sale. PetVivo’s strategy leverages human therapies for companion animals to achieve accelerated timelines to revenue compared to more stringently regulated pharmaceuticals. The company holds a portfolio of twelve patents and six trade secrets protecting its biomaterials and production processes.

PetVivo Holdings filed a Current Report on Form 8-K with the Securities and Exchange Commission describing the agreement in greater detail. The move signals a consolidation of efforts around its owned intellectual property rather than licensed third-party products, potentially improving margin profiles if proprietary sales scale effectively.